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Hypertonic solutions have been studied extensively in the treatment of hypovolemic shock, both in experimental and
clinical models. Safety, efficacy, and long-term effects on animals and patients have been evaluated. The present article
reviews indications, safety, mortality rates, and outcome in patients with hemorrhagic hypovolemic shock who were treated
after admission with a hypertonic/hyperoncotic solution under strict observation in the emergency room.
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The management of severely hypo-
volemic patients has undergone signifi-
cant modifications over the past few
decades, influenced by military and ci-
vilian resuscitation experiences. Stan-
dard treatment results in significant re-
duction of severe complications, such
as multi-organ failure, and decreases
mortality in hypovolemic patients. De-
spite this progress, there are still pa-
tients who cannot fully recover even
though they undergo established
therapy1. Several studies have evalu-
ated the role of paramedics in hemody-
namic recovery of hypovolemic patients
between the scene of the accident and
arrival to emergency centers. It has
been shown that paramedics (includ-
ing those specifically trained for that
task) were faced with difficulties dur-
ing the administration of intravenous
fluids in the prehospital setting as fol-
lows: 1) difficulties in venous access in
severely hypovolemic patients, 2) dif-
ficulties in maintaining that access dur-
ing transportation, 3) difficulties in in-
fusing adequate volumes of intrave-
nous fluids, and 4) delays in transpor-
tation of the patients to emergency
wards. Average intravenous volumes
infused during the prehospital period
ranged from 500 mL to 1500 mL, clearly
inadequate for the usual plasma replace-
ment volume for severely hemorrhaged
patients. Recent experimental animal
studies have shown that the adminis-
tration of hypertonic solutions im-
proves hemodynamic parameters in
hypovolemic shock, with a significant
impact on survival2-8. Hypertonic solu-
tions with varied salt concentrations
have been tested, ranging from 1.5%
NaCl to 24% NaCl (1000 mOsm/L to 8000
mOsm/L).  Several clinical studies have
shown that the infusion of hypertonic/
hyperoncotic solutions is safe and con-
sistently reverses hemodynamic alter-
ations present in shock9-12. Felipe (1980)
used a hypertonic NaCl solution (7.5%)
in 12 patients admitted to the intensive
care unit with “refractory shock”. The
infusion of this solution resulted in im-
mediate increase in blood pressure and
urine output. Nine patients survived
and were discharged from the hospital.
Most studies with hypertonic/
hyperoncotic solution for the treatment
of hypovolemic patients have been de-
signed to address the issue of
prehospital volume replacement, both
in civilian and military settings. The
studies were usually carried out by para-
medics present at the scene of the acci-
dent who infused the solution before
and during and transport to the corre-
sponding medical facility. In these stud-
ies, the hemodynamic and physiologi-
cal alterations associated with the ad-
ministration of hypertonic solutions
were evaluated immediately after the in-
fusion of the solution and only at the
arrival in the emergency room.
MAY-JUNE REV. HOSP. CLÍN. FAC. MED. S. PAULO 57(3):124-128, 2002
125
Emergency Room studies
Since the early 1980s, we have de-
signed studies in the Department of
Surgery of Hospital das Clínicas of the
University of São Paulo School of Medi-
cine that were performed totally within
the emergency ward under constant
medical observation. Those studies
enabled us to closely observe patients
and collect information related to the
use of hypertonic solutions in trauma
patients. In 1985, we performed a con-
trolled non-randomized study in pa-
tients with hypovolemic hemorrhage to
evaluate blood pressure response to
hypertonic solution administered
through peripheral vein (cephalic vein),
as well as to evaluate the safety of this
new treatment modality. Patients that
received hypertonic solution (7.5%
NaCl) showed an immediate increase in
blood pressure. These results were
found throughout the study. No sig-
nificant side effects were seen in this
limited study. A hypertonic/
hyperoncotic solution was introduced
into clinical trials by Vassar, at the Uni-
versity of California, Davis, in a
prehospital treatment study of hypov-
olemic trauma patients. In the double-
blind study, the solution (HSD—250 mL
7.5% NaCl + 6% dextran) was adminis-
tered to patients with a systolic blood
pressure < 100 mm Hg. Upon arrival to
the emergency room, patients that re-
ceived HSD had significantly higher
blood pressure and exhibited a trend
towards better overall survival. Al-
though the hemodynamic amelioration
is obvious, most clinical studies have
failed to show significant impact on
long-term survival or complication
rates.
We performed another randomized
double-blinded study in the emergency
room, comparing the efficacy and the
safety of HSD and hypertonic 7.5%
NaCl. This study included 105 patients
admitted with hemorrhagic hypov-
olemia. Mean arterial blood pressure
increased immediately and significantly
in the patients that received either hy-
pertonic solution, compared to isotonic
saline. No significant differences were
seen between the two hypertonic solu-
tions (HSD and 7.5% NaCl). There were
no side effects associated with hyper-
tonic infusion. The number of patients
in the study did not allow for clear
evaluation of the impact of hypertonic
treatment on immediate and long-term
survival. To address the survival issue,
a more extensive study with 2 arms
(HSD x isotonic saline) was then de-
signed to include a sufficient number
of patients 13. This study evaluated the
effects of hypertonic/hyperoncotic so-
lutions infused in the treatment of hy-
povolemic shock in patients, as well as
the subsequent identification of prog-
nostic factors that might more accu-
rately predict the patients who are go-
ing to benefit from the administration
of hypertonic solutions.
PATIENTS  AND  METHODS
Patients were considered eligible for
the present study if they were treated
for hemorrhagic hypovolemia and re-
quired blood volume expansion. All
patients were admitted to the emer-
gency room (ER) between February
1991 and November 1992. Patients were
excluded if they were under the age of
16 years, pregnant, or had cardiac or
renal failure prior to their acute hemor-
rhagic episode, or arrived with cardiac
arrest (absence of palpable pulse or
electrical activity on EKG). Informed
consent was not obtained because of
the urgency of the situation and the
unavailability of family members in most
cases. The Ethical Committee of our in-
stitution approved the research proto-
col.
Treatment protocol
Two hundred and twelve patients
were included in the study protocol and
received either an intravenous bolus
infusion of 250 mL of hypertonic/
hyperoncotic 7.5% NaCl + 6% dextran
70 (HSD) or an isotonic 0.9% NaCl (IS)
solution in a double-blind randomized
fashion. The solutions were adminis-
tered by peripheral or central intrave-
nous route, depending on the first avail-
able venous access.
The study solutions were prepared
by a pharmaceutical company (B. Braun
Laboratories) and were provided in
coded, externally identical vials contain-
ing a 250 mL volume of the solutions.
Neither the investigators nor the ER
team had any control or knowledge of
the infused solution during the entire
study period. Following the administra-
tion of the test solution, the patients
were treated in accordance with the
standard and emergency management
protocols in our institution. Standard
treatment was administered in the ER
by staff physicians and senior resi-
dents. One of us was always present in
the ER from the moment the patient was
included in the study and for daily fol-
low up thereafter. Standard treatment
in the ER included the infusion of crys-
talloid solutions to reach a systolic pres-
sure higher than 100 mm Hg and blood
infusion to maintain a hematocrit level
higher than 29%. All diagnostic and
therapeutic procedures were performed
by staff physicians as indicated, regard-
less of whether the patient was in our
study.
Outcome assessment
All patients were followed up from
admission until their discharge, demise,
or end of the 30-day observation pe-
riod, whichever was first reached. Pre-
treatment prognostic factors were de-
termined immediately before the infu-
sion of the test solution as follows: Age
and gender of the patient, the cause of
hypovolemia, Revised Trauma Score
(RTS), Glasgow Coma Scale (GCS), and
mean arterial pressure (MAP). Intrave-
nous fluid volumes required to resusci-
tate and maintain hemodynamics in
these patients during the first 60 min-
utes after admission were registered,
and MAP was determined at 15-minute
intervals. Survival was evaluated at 24
hours and after 30 days. Patients were
classified as having been discharged if
they left the hospital alive. Complica-
tion rates were evaluated on a daily
basis. All complications were defined
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before the study as follows: overall
complications (any complication), renal
failure (presence of oliguria, decreased
glomerular filtration rate, or increased
blood urea nitrogen or creatinine lev-
els), cardiac complications (dysrhyth-
mias, cardiac failure), pulmonary failure
(PaO2 < 60 mm Hg, PCO2 > 55 mm Hg,
increased alveolar - capillary gradient),
infectious complications (evidence of
bacteremia, positive culture, or purulent
discharge), neurologic complications
(seizures or brain damage not ac-
counted for by head injury).
Table 1 presents baseline character-
istics of 212 patients admitted to the
ER and included in our study. There
were no significant differences between




increased MAP, compared with the IS
group. Blood pressure increased at a
higher rate in HSD-treated patients fol-
lowing hypertonic infusion. The need
for intravenous crystalloid infusion
was significantly greater in patients that
received IS (median 2500 mL, range 0-
5000 mL), than in the HSD group (me-
dian 1500 mL, range 0-5000 mL). There
were no differences in blood product
derivatives infused between the 2
groups, since only 5 patients in the IS
group and 6 patients in the HSD group
received red blood cell concentrates
during the initial resuscitation period.
Forty-eight patients in the IS group
underwent a major operative procedure,
compared to 45 patients in the HSD
group.
The overall complication rate in the
IS group—27 patients (24%)—was simi-
lar to that in the HSD group—24 pa-
tients (24%). Table 2 shows the spe-
cific complications in each group dur-
ing the follow-up period. The differ-
ences were not significant.
Clinical follow up and survival
Follow-up information was col-
lected on all patients. The overall 30-
day survival rate for all our patients was
67%. There was a significant difference
(P = 0.02199) in overall survival rate
between HSD and IS groups (Fig. 1).
The 24-hour survival rate was signifi-
cantly lower in the IS group (72%), com-
pared with the HSD group (87%) (P =
0.007). Following this period, the dif-
ference between the survival curves
tended to decrease gradually, and after
the 15th day of the study, the groups
showed similar survival rates. This find-
ing could be due to death of the more
severely injured patients that survived
the first 24 hours of trauma and were
transferred to the ICU in critical condi-
tion. Most of the deaths in the IS group
occurred in the first 5 days. The overall
mortality rate in the IS group was 36%
(40/111); 31(78%) of these patients died
in the first 24 hours. The overall mortal-
ity rate in the HSD group was 27% (27/
101); 13 patients (48%) died in the first
24 hours. More patients died in the HSD
group in the next 29 days (14 patients)
than in the IS group (9 patients).
The univariate Cox analysis identified
pretreatment variables as potential pre-
dictors of both short-term (24 hours) sur-
Table 1 - Patient characteristics upon admission.
Isotonic solution (n=111) Hypertonic solution + dextran(n=101)
Age (years) Median: 29 (16-89) median: 30 (16-83)
Gender M: 92; F: 19 M: 93; F: 8
Revised Trauma Score Median: 13 (4-16) median: 14 (4-16)
Glasgow Coma Score Median: 14 (3-15) median: 14 (3-15)
Cause of hypovolemia:
 Gunshot 33 patients 35 patients
 Stab 13 patients 13 patients
 Blunt 50 patients 37 patients
 Other 15 patients 16 patients
Organs wounded Median 2 (1-16) median 2 (1-8)
Median arterial
pressure AP (mm Hg) Median 63 (0-106) median 65 (0-95)
Table 2 - Major complications in the patients.
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vival and long-term survival of the pa-
tients entered into the study. For selected
univariate predictors, clinically relevant
categories were identified. Direct
univariate predictors of 24-hour survival
benefit following the administration of
HSD were the RTS < 14, MAP < 70 mm
Hg, and GCS < 12. Age, sex, and cause of
hypovolemia were not significant prog-
nosticators of short-term survival benefit
associated with hypertonic/hyperoncotic
administration. In the multivariate Cox
analysis of baseline admission variables,
MAP < 70 mm Hg (P < 0.01) and RTS < 14
(P < 0.01) were identified as independent
predictors for 24-hour survival in the
group that received HSD.
HSD infusion was associated with
a significant long-term survival only in
patients admitted with MAP < 70 mm
Hg. All other variables were not signifi-
cant. The analysis of the prognostic
factors showed that RTS, MAP, and
GCS significantly predicted a 24-hour
survival benefit in the HSD group. All
other factors analyzed (age, sex, and
cause of hypovolemia) were not corre-
lated with the outcome following the
infusion of hypertonic solution. Multi-
variate analyses showed that only RTS
and MAP were significant as good
prognosticators in the HSD group.
When evaluated for overall survival,
hypertonic infusion benefited signifi-
cantly only patients with MAP < 70 mm
Hg (P < 0.01). No other factor was pre-
dictive of a favorable outcome follow-
ing the administration of HSD.
DISCUSSION
The present double-blind random-
ized study evaluated the possibility of
defining more clearly the groups of hy-
povolemic patients that would eventu-
ally benefit from the administration of a
hypertonic/hyperoncotic solution. Pa-
tients included in the study were dis-
tributed in a balanced manner between
the 2 groups, despite the slight, but not
significant, higher incidence of blunt
trauma in the IS group. The number of
major organs wounded by the trauma
was similar, and MAP on admission was
not different in the 2 groups. The esti-
mated overall 30-day mortality of the pa-
tients included in the study was 33%.
Most of the patients in both groups pre-
sented with blunt trauma, with 50% hav-
ing more than 2 organs affected by sig-
nificant lesions. When compared to our
previous study completed in the late
1980s10, the policy of the staff team of
the trauma service at our hospital is now
oriented toward a diminished use of
blood transfusions, at least in the resus-
citation period (first 60 minutes). Thus,
only 5 patients in the IS group and 6
patients in the HSD group received any
red blood-cell transfusion. There was no
difference between the 2 groups in the
amount of blood products transfused.
On the other hand, significantly greater
crystalloid volumes were needed to im-
prove hemodynamics in patients receiv-
ing exclusively isotonic saline. These
results confirm our previously published
data, as well as those of others11. Al-
though we observed a clear difference
in the volumes infused and in the hemo-
dynamic stability associated with the hy-
pertonic infusion, we did not observe
any influence on complication rates in
our patients in any group. Other studies
have not shown any significant differ-
ences in overall complication rates in
patients that received hyperosmotic so-
lutions15. Although the differences were
not significant, we observed more fre-
quent complications directly related to
shock and hypovolemia (renal, cardiac,
and pulmonary complications) in the IS
patients, while the patients in the HSD
group presented more infectious and
neurological complications. These data
might indicate a favorable trend in pa-
tients receiving HSD toward milder ef-
fects of hypovolemia on organ failure.
Almost half of the patients in either group
underwent a major surgical procedure.
Mattox detected a survival benefit in
patients undergoing a major operation if
treated with hypertonic sodium solution
+ dextran in a prehospital setting15. In
the present study, we did not establish
beforehand the assessment of operative
procedures as a prognostic factor, so we
did not analyze this factor in our study.
The overall 30-day mortality rate for all
our patients was 33%. The present
study showed a significant effect of HSD
infusion on 24-hour and overall survival
rates in hypovolemic patients admitted
to the ER (P < 0.01). The 24-hour sur-
vival rate was significantly lower in the
patients that received isotonic infusion,
compared with HSD. After the 15th day
of the study, the groups showed similar
survival rates. This result could have
been caused by the delayed death of
more severely injured patients that were
successfully resuscitated in the first 24
hours following trauma and were trans-
ferred to the ICU in critical condition.
Most of the deaths in the IS group oc-
curred in the first 5 days. The overall
mortality rate in the HSD group (27%)
was less than that of the IS group (36%).
Approximately half of the deaths in the
HSD group occurred in the first 24 hours
as compared to 78% in the IS group.  One
the other hand, more patients died in the
HSD group in the next 29 days (14 pa-
tients) than in the IS group (9 patients).
No injury severity scores were calculated
for the patients included in this study
(this was not established in our proto-
col beforehand). Consequently, the pre-
dicted survival for each patient was not
evaluated in our study.
In a univariate analysis, the pre-
treatment variables, RTS, MAP, and
GCS, were identified as potential pre-
dictors of both short- and long-term
survival of the patients included in the
study. Age, gender, and cause of hy-
povolemia were not significant prog-
nosticators of short-term survival. In
the multivariate analysis, baseline ad-
mission variables, MAP and RTS, were
identified as independent predictors
for 24-hour survival in the group that
received HSD. The administration of a
hypertonic/hyperoncotic solution in
the emergency room positively af-
fected the short-term survival rate,
mostly in severely injured and hypov-
olemic patients, compared with stan-
dard isotonic resuscitation.
HSD infusion was associated with
a significantly greater long-term sur-
vival rate only in patients admitted
with MAP < 70 mm Hg. All other fac-
tors analyzed (RTS, GCS, age, sex, and
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cause of hypovolemia) did not influ-
ence the outcome following the infu-
sion of hypertonic solution.
CONCLUSIONS
This is the first prospective random-
ized study performed in one center that
has demonstrated an outcome benefit
following the administration of hyper-
tonic solutions in the initial treatment
of hypovolemic patients admitted to the
emergency room. The study confirms
previous reports on hemodynamic and
volume infusion requirement advan-
tages over isotonic treatment, as well
as the safety of intravenous 250 mL
bolus infusion of 7.5% NaCl + 6% dex-
tran 70. Our data should be validated in
a prospective study by looking specifi-
cally at the patients with projected ben-
efits, mainly because our stratification
of the subgroups of patients was only
possible after all patients were treated,
even though the stratification method
was established in the protocol design.
More studies are needed to identify the
survival benefits in patients treated with
hypertonic solutions in the prehospital
setting. Differences in ambulance time
required for arrival at the scene of the
accident, transportation time, and vari-
ability in standard treatments between
trauma centers require studies with
larger populations in prehospital-treat-
ment multicenter trials to clearly show
advantages of the hyperosmotic treat-
ment.
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RESUMO RHCFAP/3082
YOUNES RN e col. - Solução hiper-
tônica hiperoncótica em pacientes
com hipovolemia: experiência na
sala de admissão. Rev. Hosp. Clín.
Fac. Med. S. Paulo 57(3): 2002.
As soluções hipertônicas têm sido
estudadas no tratamento de choque
hipovolêmico, tanto em protocolos
experimentais quanto clínicos. A
eficácia, a segurança e os efeitos a
longo prazo em animais e pacientes
foram avaliados. O presente estudo
apresenta uma revisão da literatura
sobre as indicações, as taxas de
morbidade e de mortalidade e a
evolução de pacientes com choque
hipovolêmico, admitidos e tratados com
soluções hipertônicas/hiperoncóticas,
admitidos e tratados sob observação
contínua na sala de emergência do
pronto socorro.
DESCRITORES:   Hipovolemia.
Hemorragia.    Solução hipertônica.
Pronto socorro.
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